Dr Leora Horn talks to ecancer at the ASCO 2012 Annual meeting in Chicago about three abstracts on non-small cell and small cell lung cancer.

The first abstract involved crizotinib, which treats lung cancer cases with the rare ROS1 fusion mutation. Only 1% of non-small cell lung cancer has this targetable mutation. The trial aimed to discover the extent of crizotinib's efficacy.

The second abstract showed results from a phase 1 trial involving the PD1 drug MDX-1106 in multiple line settings against small cell lung cancer.

Results showed response in multiple subsets of lung cancer with durable responses. The final abstract presented preliminary data on RET fusions in non-small cell long cancer patients.